Candida-elicited Murine Th17 Cells Express High Ctla-4 Compared with Th1 Cells and Are Resistant to Costimulation Blockade

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2014 Feb 5

PMID 24493820

Citations 19

Authors

Scott M Krummey

Tamara L Floyd

Danya Liu

Maylene E Wagener

Mingqing Song

Mandy L Ford

Affiliations

Soon will be listed here.

Abstract

Effector and memory T cells may cross-react with allogeneic Ags to mediate graft rejection. Whereas the costimulation properties of Th1 cells are well studied, relatively little is known about the costimulation requirements of microbe-elicited Th17 cells. The costimulation blocker CTLA-4 Ig has been ineffective in the treatment of several Th17-driven autoimmune diseases and is associated with severe acute rejection following renal transplantation, leading us to investigate whether Th17 cells play a role in CD28/CTLA-4 blockade-resistant alloreactivity. We established an Ag-specific model in which Th1 and Th17 cells were elicited via Mycobacterium tuberculosis and Candida albicans immunization, respectively. C. albicans immunization elicited a higher frequency of Th17 cells and conferred resistance to costimulation blockade following transplantation. Compared with the M. tuberculosis group, C. albicans-elicited Th17 cells contained a higher frequency of IL-17(+)IFN-γ(+) producers and a lower frequency of IL-10(+) and IL-10(+)IL-17(+) cells. Importantly, Th17 cells differentially regulated the CD28/CTLA-4 pathway, expressing similarly high CD28 but significantly greater amounts of CTLA-4 compared with Th1 cells. Ex vivo blockade experiments demonstrated that Th17 cells are more sensitive to CTLA-4 coinhibition and therefore less susceptible to CTLA-4 Ig. These novel insights into the differential regulation of CTLA-4 coinhibition on CD4(+) T cells have implications for the immunomodulation of pathologic T cell responses during transplantation and autoimmunity.

Citing Articles

IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice.

Muckenhuber M, Mengrelis K, Weijler A, Steiner R, Kainz V, Buresch M Nat Commun. 2024; 15(1):4309.

PMID: 38830846 PMC: 11148062. DOI: 10.1038/s41467-024-48574-w.

The Entangled World of Memory T Cells and Implications in Transplantation.

Alexander K, Ford M Transplantation. 2023; 108(1):137-147.

PMID: 37271872 PMC: 10696133. DOI: 10.1097/TP.0000000000004647.

T cell plasticity in renal autoimmune disease.

Soukou S, Huber S, Krebs C Cell Tissue Res. 2021; 385(2):323-333.

PMID: 33937944 PMC: 8088832. DOI: 10.1007/s00441-021-03466-z.

Induction of the IL-1RII decoy receptor by NFAT/FOXP3 blocks IL-1β-dependent response of Th17 cells.

Kim D, Kim H, Cho S, Yoo S, Kim W, Yeon H Elife. 2021; 10.

PMID: 33507149 PMC: 7872515. DOI: 10.7554/eLife.61841.

A TRP1-marker-based system for gene complementation, overexpression, reporter gene expression and gene modification in Candida glabrata.

Sprenger M, Brunke S, Hube B, Kasper L FEMS Yeast Res. 2020; 20(8).

PMID: 33289831 PMC: 7787354. DOI: 10.1093/femsyr/foaa066.

References

Benghiat F, Craciun L, De Wilde V, Dernies T, Kubjak C, Lhomme F . IL-17 production elicited by allo-major histocompatibility complex class II recognition depends on CD25posCD4pos T cells. Transplantation. 2008; 85(7):943-9. DOI: 10.1097/TP.0b013e31816a5ae7. View

Brehm M, Markees T, Daniels K, Greiner D, Rossini A, Welsh R . Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol. 2003; 170(8):4077-86. DOI: 10.4049/jimmunol.170.8.4077. View

Chung B, Kim K, Sun I, Choi S, Park H, Jeon E . Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients. Immunol Lett. 2011; 141(2):181-9. DOI: 10.1016/j.imlet.2011.10.002. View

Williams M, Onami T, Adams A, Durham M, Pearson T, Ahmed R . Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol. 2002; 169(10):5387-91. DOI: 10.4049/jimmunol.169.10.5387. View

Hue S, Ahern P, Buonocore S, Kullberg M, Cua D, McKenzie B . Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006; 203(11):2473-83. PMC: 2118132. DOI: 10.1084/jem.20061099. View

Falkenburg W, Melenhorst J, van de Meent M, Kester M, Hombrink P, Heemskerk M . Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol. 2011; 187(5):2824-33. DOI: 10.4049/jimmunol.1100852. View

Alegre M, Frauwirth K, Thompson C . T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2002; 1(3):220-8. DOI: 10.1038/35105024. View

Chatterjee M, Rauen T, Kis-Toth K, Kyttaris V, Hedrich C, Terhorst C . Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. J Immunol. 2011; 188(3):1206-12. PMC: 3262878. DOI: 10.4049/jimmunol.1102773. View

Lu Y, Schneider H, Rudd C . Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. Blood. 2012; 120(23):4560-70. PMC: 3557398. DOI: 10.1182/blood-2012-04-421420. View

10.

Larsen C, Pearson T . The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol. 1997; 9(5):641-7. DOI: 10.1016/s0952-7915(97)80043-x. View

11.

Lee Y, Awasthi A, Yosef N, Quintana F, Xiao S, Peters A . Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012; 13(10):991-9. PMC: 3459594. DOI: 10.1038/ni.2416. View

12.

Ndejembi M, Teijaro J, Patke D, Bingaman A, Chandok M, Azimzadeh A . Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol. 2006; 177(11):7698-706. DOI: 10.4049/jimmunol.177.11.7698. View

13.

Linsley P, Nadler S . The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev. 2009; 229(1):307-21. DOI: 10.1111/j.1600-065X.2009.00780.x. View

14.

Adams A, Pearson T, Larsen C . Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev. 2003; 196:147-60. DOI: 10.1046/j.1600-065x.2003.00082.x. View

15.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

16.

Adams A, Williams M, Jones T, Shirasugi N, Durham M, Kaech S . Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003; 111(12):1887-95. PMC: 161424. DOI: 10.1172/JCI17477. View

17.

Hirota K, Duarte J, Veldhoen M, Hornsby E, Li Y, Cua D . Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011; 12(3):255-63. PMC: 3040235. DOI: 10.1038/ni.1993. View

18.

Amezcua-Guerra L, Hernandez-Martinez B, Pineda C, Bojalil R . Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut. 2006; 55(7):1059-60. PMC: 1856333. DOI: 10.1136/gut.2006.095539. View

19.

Jager A, Dardalhon V, Sobel R, Bettelli E, Kuchroo V . Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009; 183(11):7169-77. PMC: 2921715. DOI: 10.4049/jimmunol.0901906. View

20.

Santarlasci V, Maggi L, Capone M, Querci V, Beltrame L, Cavalieri D . Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity. 2012; 36(2):201-14. DOI: 10.1016/j.immuni.2011.12.013. View